清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies

罗氟司特 医学 药代动力学 耐受性 最大值 生物利用度 银屑病 药理学 加药 曲线下面积 口服 体表面积 不利影响 内科学 皮肤病科 慢性阻塞性肺病
作者
Archie W. Thurston,David W. Osborne,Scott Snyder,Robert Higham,Patrick Burnett,David R. Berk
出处
期刊:American Journal of Clinical Dermatology [Adis, Springer Healthcare]
卷期号:24 (2): 315-324 被引量:5
标识
DOI:10.1007/s40257-022-00741-9
摘要

Most patients with chronic plaque psoriasis receive topical treatment; however, available options lack a balance of efficacy with long-term safety and tolerability. Roflumilast cream 0.3% is a highly potent phosphodiesterase 4 (PDE4) inhibitor approved by the US FDA for treatment of psoriasis.The aim of this study was to define the pharmacokinetic (PK) profile of roflumilast delivered topically from a phase I maximal usage study and data from phase II and phase III studies.PK data for roflumilast and the active metabolite, roflumilast N-oxide, were determined from a phase I PK and safety maximal usage study of roflumilast cream 0.3% applied once daily for 14 days in patients with plaque psoriasis affecting body surface area (BSA) ≥20% (N = 26). Serial plasma samples were obtained on Days 1 and 15 to determine maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC). Plasma concentrations were also assessed at Weeks 3, 4, and 5 for terminal half-life (t½). Concentrations of roflumilast and roflumilast N-oxide in skin were assessed at Day 28 for 14 patients with psoriasis in a phase I/IIa study of once-daily roflumilast cream 0.5% and 0.15% for 28 days. Systemic exposure (Ctrough and AUC) of roflumilast and roflumilast N-oxide in two phase III trials (DERMIS-1, n = 245; DERMIS-2, n = 250) of roflumilast cream 0.3% for 8 weeks was assessed at Weeks 4 and 8.Bioavailability of roflumilast cream 0.3% after topical administration was 1.5%. Unlike after oral dosing, the plasma concentration-time curve was flat, with a peak-to-trough ratio of 1.2. Roflumilast N-oxide concentrations were eightfold higher than roflumilast concentrations. The t½ in adult patients was 4.0 days for roflumilast and 4.6 days for roflumilast N-oxide following the last dose administered. Steady state was reached by Day 15. Concentrations of roflumilast in skin were, on average, 126- and 61.8-fold higher than corresponding mean plasma Ctrough following administration of roflumilast cream 0.15% and 0.5% daily for 28 days. Roflumilast N-oxide was quantifiable in only one skin sample (N = 27). Following 8 weeks of treatment in DERMIS-1, mean plasma Ctrough of roflumilast was 1.78 ng/mL, and 9.86 ng/mL for roflumilast N-oxide. In DERMIS-2, mean plasma Ctrough was 1.72 ng/mL and 10.2 ng/mL, respectively. In the maximal usage study (mean BSA: 27.5%), eight patients (30.8%) experienced adverse events (AEs) and all were mild or moderate, with no reports of diarrhea, headache, insomnia, or application-site pain; no patients discontinued treatment due to an AE.Topical administration of roflumilast cream 0.3% results in concentrations in skin 126- and 61.8-fold higher relative to plasma, which are much higher than expected to be achievable with oral dosing. PDE4 inhibition in the skin is likely due to roflumilast as compared with its active metabolite, as there is no significant conversion to roflumilast N-oxide in the skin. Consistent with reservoir formation and retention of drug in the stratum corneum, roflumilast is slowly released from the skin (t½ 4 days) and peak-to-trough ratio is 1.2.NCT04279119, NCT03392168, NCT04211363, NCT04211389.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
里昂义务完成签到,获得积分10
5秒前
里昂义务发布了新的文献求助10
7秒前
光合作用完成签到,获得积分10
20秒前
fanssw完成签到 ,获得积分10
1分钟前
1分钟前
liuzhigang完成签到 ,获得积分10
1分钟前
JrPaleo101完成签到,获得积分10
1分钟前
Hiram完成签到,获得积分10
1分钟前
1分钟前
研友_nxw2xL完成签到,获得积分10
2分钟前
muriel完成签到,获得积分10
2分钟前
2分钟前
3分钟前
cadcae完成签到,获得积分20
3分钟前
林文隆完成签到,获得积分10
3分钟前
萱棚完成签到 ,获得积分10
4分钟前
温暖的蚂蚁完成签到 ,获得积分10
4分钟前
希望天下0贩的0应助liudy采纳,获得10
4分钟前
雪流星完成签到 ,获得积分10
4分钟前
4分钟前
飞翔的企鹅完成签到,获得积分10
4分钟前
4分钟前
liudy完成签到,获得积分10
4分钟前
liudy发布了新的文献求助10
4分钟前
5分钟前
5分钟前
5分钟前
玖月完成签到 ,获得积分10
5分钟前
6分钟前
6分钟前
Lucas应助科研通管家采纳,获得10
6分钟前
6分钟前
ChatGPT完成签到,获得积分10
6分钟前
传奇3应助asdf采纳,获得10
7分钟前
7分钟前
naczx完成签到,获得积分0
7分钟前
8分钟前
8分钟前
asdf发布了新的文献求助10
8分钟前
Hello应助hongtao采纳,获得10
8分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3965722
求助须知:如何正确求助?哪些是违规求助? 3510967
关于积分的说明 11155723
捐赠科研通 3245436
什么是DOI,文献DOI怎么找? 1792920
邀请新用户注册赠送积分活动 874201
科研通“疑难数据库(出版商)”最低求助积分说明 804229